Transplantation & Cellular Therapy
The latest news, research, and perspectives in transplantation and cellular therapy. Hematopoietic cell transplantation involves replacing unhealthy bone marrow with healthy stem cells in patients with hematologic disorders. In the growing field of non-transplant cellular therapies, including chimeric antigen receptor T-cell therapies, patient- or donor-derived cells are being explored for the treatment and potential cure of blood cancers.
Advertisement
In approximately 12,000 reports of adverse events, the researchers found 19 cases of T-cell malignancies after CAR-T.
The investigators reviewed case reports of patients 20 years old and younger who underwent therapy for BPDCN.
HMA plus venetoclax was found to be effective and well tolerated in patients with AML who relapsed after HSCT.
Adding ofatumumab to reduced intensity conditioning is safe and effective in high-risk B-cell non-Hodgkin lymphoma.
The study also explored the role of this combination in transitioning patients to HSCT.
The award grants $100,000 to a postdoctoral or early-career oncology researcher from a racial/ethnic minority group.
Advertisement
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
Drs. Dahiya and Spiegel return for the second half of a discussion on reports of secondary T-cell malignancies after CAR-T.
Approach-oriented coping was associated with higher quality of life and lower symptoms of depression and anxiety.
The study used public data from various online sources related to approved CAR-T therapies for MM.
The mandate could affect moving CAR-T therapies into earlier lines of therapy for multiple myeloma.
This manufacturing process change results in a shorter manufacturing time for axi-cel from 16 days to 14 days.
ZUMA-7 showed that axi-cel significantly improved OS compared with standard of care in relapsed or refractory LBCL.
The latest HemOnc Pulse episode looks at the science behind the statement from the FDA on the risk of CAR-T therapies.
Patients' coping strategies prior to HSCT had significant effects on their psychological distress and quality of life.
Shernan Holtan, MD, and the hosts discuss recent data on graft versus host disease prophylaxis.
GVHD affects approximately 30,000 Americans, according to Dr. Michael Chancellor, Chief Medical Officer at Lipella.
The investigation is "likely not going to change the risk-benefit profile of these approved products," Dr. Chari said.
Dr. Osman discussed menin inhibitors for leukemia, and axatilimab treatment for graft-versus-host disease.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.